Send to

Choose Destination
Diabetologia. 2018 Oct;61(10):2134-2139. doi: 10.1007/s00125-018-4678-z. Epub 2018 Aug 22.

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.

Author information

Department of Internal Medicine I, Nephrology, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.
Department of Internal Medicine I, Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.


Individuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart failure. Over recent decades, numerous cardiovascular outcome trials in individuals with type 2 diabetes have been published, with data showing a reduction of cardiovascular morbidity and mortality by sodium-glucose cotransporter 2 (SGLT2) inhibitors. These results not only provide novel therapeutic options for this high-risk population but also advance our current understanding of cardiovascular risk reduction in diabetes. The current overview article summarises these aspects and discusses future treatment strategies with SGLT2 inhibitors in diabetic and non-diabetic individuals with chronic kidney disease, liver disease and heart failure.


Diabetes mellitus; Diabetic kidney disease; Heart failure; Non-alcoholic fatty liver disease; Non-diabetic chronic kidney disease; Review

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center